Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

1.56
-0.1650-9.59%
Volume:2.25M
Turnover:3.62M
Market Cap:129.03M
PE:-0.54
High:1.69
Open:1.66
Low:1.52
Close:1.72
Loading ...

Editas Medicine Inc : RBC Cuts Target Price to $4 From $5

THOMSON REUTERS
·
13 Dec 2024

Editas Medicine Inc : Truist Securities Cuts to Hold From Buy

THOMSON REUTERS
·
13 Dec 2024

Editas Medicine (EDIT) Receives a Buy from TD Cowen

TIPRANKS
·
13 Dec 2024

Cautious Outlook for Editas Medicine Amid Strategic Shift and Competitive Challenges

TIPRANKS
·
13 Dec 2024

Editas Medicine downgraded to Hold from Buy at Stifel

TIPRANKS
·
13 Dec 2024

Editas Medicine: Navigating Uncertainty with a Hold Rating Amid Strategic Shifts and Development Challenges

TIPRANKS
·
13 Dec 2024

Editas Medicine Focuses on In Vivo Gene-Editing Medicines, Ends Reni-Cel Development to Cut Costs

MT Newswires Live
·
13 Dec 2024

BRIEF-Editas Medicine Announces Strategic Transition To In Vivo Gene Editing Company

Reuters
·
13 Dec 2024

Editas Medicine Pivots Gene Editing Strategy, Cutting 65% of Workforce

Dow Jones
·
13 Dec 2024

Editas Medicine Inc - Expected Costs of $55 Million to $70 Million

THOMSON REUTERS
·
13 Dec 2024

Editas Medicine Inc - Discontinues Clinical Development of Reni-Cel Program

THOMSON REUTERS
·
13 Dec 2024

Editas Medicine Inc - Chief Medical Officer Baisong MEI to Step Down Effective Dec 31, 2024

THOMSON REUTERS
·
13 Dec 2024

Editas to reduce about 65% of its workforce over the next six months

Reuters
·
13 Dec 2024

Editas Medicine Inc: Initiating Cost Savings Measures and Reduction in Headcount to Align Workforce

THOMSON REUTERS
·
13 Dec 2024

Editas Medicine Inc: Jessica Hopfield, Has Been Named Chair of Board, Effective December 31

THOMSON REUTERS
·
13 Dec 2024

Editas Medicine Inc - Initiated Reduction in Headcount to Eliminate Approximately 65% of Its Workforce Over Next Six Months

THOMSON REUTERS
·
13 Dec 2024